1 |
Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet oncol 2005;6:392-400
DOI
ScienceOn
|
2 |
Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004;45:1358-65
|
3 |
Honore P, Rogers SD, Schwei MJ, et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000;98:585-98
DOI
ScienceOn
|
4 |
Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP. Molecular mechanisms of cancer pain. Nat Rev Cancer 2002;2:201-9
DOI
ScienceOn
|
5 |
Urch C. The pathophysiology of cancer-induced bone pain: current understanding. Palliat Med 2004;18:267-74
DOI
|
6 |
Steenland E, Lee J, van Houwelingen H, et al. The effect of single fraction compared to multiple fractions in painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiat Oncol 1999;52:101-9
DOI
ScienceOn
|
7 |
Hoskin PJ, Stratford MRL, Folkes LK, Regan J, Yarnold JR. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet 2000;355:1428-9
DOI
ScienceOn
|
8 |
Blake GM, Zivanovic MA, McEwan AJ, et al. Sr-89 therapy:strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986;12:447-54
|
9 |
Nair N. Relative efficacy of P and Sr in palliation in skeletal metastases. J Nucl Med 1999;40:256-61
|
10 |
Sciuto R, Festa A, Pasqualoni R, et al. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat 2001;66:101-9
DOI
ScienceOn
|
11 |
Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002;20:189-96
DOI
ScienceOn
|
12 |
Han SH, Zonneberg BA, de Klerk JM, et al. Re -etidronate in breast cancer patients with metastatic bone pain. J Nucl Med 1999;40:639-42
|
13 |
Hoskin PJ, Ford HT, Harmer CL. Hemibody irradiation for metastatic bone pain in two histologically distinct groups of patients. Clin Pathol 1991;1:67-9
|
14 |
Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001;42:895-906
|
15 |
LoRusso P. Analysis of skeletal-related events in breast cancer and response to therapy. Semin Oncol 2001;28(4 suppl 11):22-27
|
16 |
Friedland J. Local and systemic radiation for palliation of metastatic disease. Urol Clin North Am 1999;26:391-402
DOI
|
17 |
Treede RD, Meyer RA, Raja SN, Campbell JN. Peripheral and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol 1992;38:397-421
DOI
ScienceOn
|
18 |
Liepe K, Hliscs R, Kropp J, et al. Dosimetry of Rehydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J Nucl Med 2003;44:953-60
|
19 |
Srivastava SC, Atkins HL, Krishnamurthy GT, et al. Treatment of metastatic bone pain with tin-117m stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study. Clin Cancer Res 1998;4:61-8
|
20 |
Parfitt AM. Bone remodeling, normal and abnormal: a biological basis for the understanding of cancer-related bone disease and its treatment. Can J Oncol 1995;5(suppl 1):1-10
|
21 |
Buchali K, Correns HJ, Schuerer M, et al. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 1988;14: 349-51
|
22 |
Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991;64:816-22
DOI
ScienceOn
|
23 |
Raisz LG. Physiology and pathophysiology of bone remodeling. Clin Chem 1999;45:1353-8
|
24 |
World Health Organization. Cancer Pain Relief and Palliative Care: Report of a WHO Expert Committee. Geneva, Switzerland: World Health Organization; 1990
|
25 |
Lipton A, Costa L, Ali SM, Demers LM. Bone markers in the management of metastatic bone disease. Cancer Treat Rev 2001;27:181-5
DOI
ScienceOn
|
26 |
Epstein M, Stewart BH, Antunez AR, et al. Half and total body irradiation for carcinoma of the prostate. J Urol. 1979;122:330-2
DOI
|
27 |
Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16:1574-81
DOI
|
28 |
Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high- energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003;21:2869-75
DOI
ScienceOn
|
29 |
Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001;28:788-98
DOI
ScienceOn
|
30 |
Robinson RG, Blake GM, Preston DF, et al. Strontium-89:treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989;9:271-81
DOI
|
31 |
Papatheofanis FJ. Quantitation of biochemical markers of bone resorption following strontium-89 chloride therapy for metastatic prostate carcinoma. J Nucl Med 1997;38:1175-9
|
32 |
Papatheofanis FJ. Serum PICP as a bone formation marker in 89Sr and external beam radiotherapy of prostatic bony metastasis. Br J Radiol 1997;70:594-8
DOI
|
33 |
Dafermou A, Colamussi P, Giganti M, et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001;28:788-98
DOI
ScienceOn
|
34 |
Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991;27:1084-6
DOI
|
35 |
Blitzer PH. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastases. Cancer 1985;55:1468- 72
DOI
ScienceOn
|
36 |
Hoskin PJ. Radiotherapy in the management of bone pain. Clin Orthop 1995;312:105-19
|
37 |
Tannock I. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 1985;3:1013-21
DOI
|
38 |
Mertens WC, Stitt L, Porter AT. Strontium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship- Am J Clin Oncol 1993;16:238-42
DOI
ScienceOn
|
39 |
McCloskey EV, MacLennan I, Drayson M, Chapman C, Dunn J, Kanis JA. Effect of clodronate on morbidity and mortality in myelomatosis. Br J Haematol 1998;100:317-25
DOI
ScienceOn
|
40 |
Powles TS, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20:3219-24
DOI
ScienceOn
|
41 |
Schraml FV, Parr LF, Ghurani S, Silverman ED. Autopsy of a cadaver containing strontium-89-chloride. J Nucl Med 1997;38: 380-2
|
42 |
Liepe K, Franke WG, Kropp J, et al. Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases. Nuklearmedizin 2000; 39:146-51
DOI
|
43 |
Dickie GJ, Macfarlane D. Strontium and samarium therapy for bone metastases from prostate carcinoma. Australas Radiol 1999;43:476-9
DOI
ScienceOn
|
44 |
Tu S, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001;357:336-41
DOI
ScienceOn
|
45 |
O'Sullivan JM, McCready VR, Flux G, et al. High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer 2002;86:1715-20
DOI
ScienceOn
|
46 |
Salazar OM, Rubin P, Hendrickson FR, et al. Single dose half body irradiation for palliation of multiple bone metastases from solid tumors. Cancer 1986;58:29-36
DOI
ScienceOn
|
47 |
Kasalicky J, Krajska V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 1998;25:1362-7
DOI
|
48 |
Eary JF, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993;34:1031-6
|